Discover published sets by community

Inhibits hepatic gluconeogenesis and attenuates intestinal absorption of glucose.

Stimulates insulin secretion from pancreatic beta cells.

Increases insulin release from the pancreas.

Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity.

Stimulates pancreatic insulin secretion by closing ATP-dependent potassium channels in pancreatic beta cells.

Inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin levels which enhance insulin secretion and suppress glucagon release.

Prevents the breakdown of incretins by inhibiting DPP-4, leading to increased insulin production and decreased glucagon secretion.

Inhibits intestinal alpha-glucosidases leading to delayed carbohydrate absorption.

Inhibits DPP-4 enzyme, which increases insulin release and decreases glucagon levels during hyperglycemia.

Inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, reducing reabsorption of glucose and increasing its excretion in urine.

DPP-4 inhibitor that enhances glycemic control through increased incretin hormone levels.

Blocks the SGLT2 protein in the kidneys, leading to more glucose being removed through urine.

Increases insulin production from the pancreas by stimulating pancreatic beta cells.

Sulfonylurea that stimulates insulin release by closing potassium channels in pancreatic beta cells.

Increases insulin secretion by binding to and inhibiting ATP-dependent potassium channels in pancreatic beta cells.

Delays carbohydrate absorption by inhibiting alpha-glucosidase enzymes in the small intestine.

Increases insulin sensitivity in adipose tissue, muscle, and the liver by activating PPAR-γ.

Stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels.

Inhibits SGLT2 in the kidneys, enhancing glucose excretion and lowering blood glucose levels.